Aim: Kidney transplantation remains the most effective treatment for end-stage kidney disease. Still, the development of de novo donor-specific antibodies (dnDSA) increases the risk of rejection and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback